In AD, the tau protein is a key target for PROTAC-based degradation, and compounds such as QC-01-175 or C8 have demonstrated the ability to selectively degrade tau, thereby reducing its aggregation and toxicity [324,325]. The gene discussed is MAPT; the disease is Alzheimer disease.